Vitagerpavac lyophilizate 0.3 ml, 5 pcs.

Vitagerpavac vaccine stimulates cellular mechanisms of human resistance to herpes simplex virus types I and II.

Indications

Herpes

Prevention of recurrent herpes infections caused by herpes simplex virus types I and II.

Active ingredient

Vaccine to prevent herpes infections

Composition

One inoculation dose (0.2 ml) contains:

acting ingredients:

Specific herpes simplex virus (HPV) antigens of types I and II, (strain “US” and strain “BH” respectively), obtained by reproduction in culture of transplanted cells of African green monkey kidney (VERO B), inactivated with formaldehyde and lyophilized with the addition of sucrose-gelatose medium as stabilizer.

Auxiliaries:

Formaldehyde not more than 200 µg/ml;

Gentamicin sulfate not more than 40 µg/ml,

sucrose not more than 0.075 g/ml;

gelatose not more than 0.01 g/ml.

How to take, the dosage

Vaccination is carried out in medical and recreational institutions by prescription and under medical supervision. Vitagerpavac vaccine is used in remission stage, not earlier than 10 days after complete disappearance of clinical manifestations of herpes infection, in case of ophthalmoherpes not earlier than 1 month.

The contents of the bottle is dissolved in 0.3 ml of solvent (sterile water for injection). To do this, the solvent is injected using a syringe with a needle into the vaccine bottle, which is then shaken until the contents are completely dissolved. The dissolved preparation should be an opalescent liquid of pink or pink and yellow color. There should be no visible mechanical inclusions. Dissolved vaccine should not be stored.

The drug is not suitable for use in bottles with compromised integrity, labeling, color change, expiration date, improper storage.

The vial is opened, the drug is dissolved and the vaccination procedure is carried out in strict adherence to asepsis.
The drug is injected intradermally in the area of the inner surface of the forearm in a single dose of 0.2 ml.

The main vaccination cycle consists of 5 injections which are carried out at 7-day intervals. The second cycle of vaccination is carried out in 7-10 days according to the same scheme.

In 6 months the second course of vaccination is carried out consisting of two cycles of 5 injections each.
Patients with severe forms of herpes infection (relapses monthly or once every 2-3 months) the drug is given at least 10-day intervals.

Interaction

There have been no cases of incompatibility with other medicines.

Special Instructions

Vaccination is carried out in medical institutions (hospital, dispensary, outpatient clinic) under the supervision of a doctor.

The vaccination is carried out in the remission stage, not earlier than 5 days after complete disappearance of clinical manifestations of herpetic infection.

If more pronounced local and general reactions occur or if the underlying process worsens, vaccination should be stopped. Vaccination can be continued after the clinical manifestations of the general reaction to the vaccine administration have completely disappeared.

All cases of more severe local and general reactions in a patient should be evaluated by a physician and recorded.

The dissolved product should be a slightly opalescent pink colored liquid.

The product is not suitable for use in vials with compromised integrity, labeling, discoloration, expiration date, or improper storage.

Dissolved vaccine must not be stored.

The opening of the bottle, dissolution of the drug and the vaccination procedure shall be carried out in strict adherence to the rules of asepsis.

Contraindications

• Herpetic infection in the active stage (relapse). Vaccination is carried out not earlier than 14 days after disappearance of clinical manifestations; with ophthalmoherpes – not earlier than 1 month
• Acute infectious and noninfectious diseases. (Vaccination is carried out not earlier than 30 days after recovery)
• Chronic diseases in the stage of exacerbation or decompensation
Cancerous tumors
• Pregnancy
• Allergy to gentamicin and other antibiotics of the aminoglycoside group

.

Side effects

Individuals may have local and general reactions after the vaccine.

Local reaction:

It is manifested by hyperemia of the skin up to 2 cm in diameter during the first day and a slight transient burning at the injection site.

The general reaction may manifest as a slight increase in temperature (not exceeding 37.5 ° C), weakness, passing without treatment.

In case of more pronounced local and general reactions or development of exacerbation of recurrent herpetic infection the drug administration should be stopped.

The vaccination can be continued after 14 days after complete disappearance of clinical manifestations of herpetic infection and general reaction to the introduction of the vaccine.

Pregnancy use

The contraindication is pregnancy.